"VLA-4 INHIBITOR COMPOUNDS"
Application IN/PCT/2001/1784/CHE published 2005-03-04, filed 2001-12-19
Compounds that selectively inhibit the binding of ligands to alpha4beta1 integrin (VLA-4) and methods for heir preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis, Also disclosed are methods of inhibiting VLA-5 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.
Applicant
DAIICHI PHARMACEUTICAL CO., & PHARMACOPEIA INC.,
of Tokyo R & d Center, 16-13, Kitakasai 1-chome, Edogawa-ku,, Tokyo 134-8630, &, of 3000 Eastpark Blvd., Cranbury, NJ 08512,, Japan & USA
Inventor
International Info
Classification: A61K 31/40; 31/4025; C07D 207/14, 401/12, 403/12
Publication Number: PCT/US00/18079
Priority Information
60/141,601 US 1999-06-30